Princy Kumar - Concepedia

Author

Princy Kumar

Also Known As

Anmar Hemaidan, Brown, Robert S., CB Hicks, Chen, Joshua, Clark, Andrew, Clifford A. Kinder, Cooper, David A., Flynn, Teri, Jeffery Kingsley, Killar, John A.

257

Publications

13.5K

Citations

H-Index

Concepts

All Affiliations

Georgetown University Georgetown University Medical Center Merck & Co., Inc., Rahway, NJ, USA (United States)National Institutes of Health University of North Carolina at Chapel Hill

About

Princy Kumar is an author at Georgetown University specializing in medicine, hiv, and clinical trials.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	29	2.3K
2	Public Health	5	5	154
3	Health Sciences	3	3	320
4	Social Sciences	1	1	26
5	African American Studies	1	1	26

Princy Kumar

Publications

9.7K

Citations

H-Index

Page 1

	Year	Citations
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 Robert Gottlieb, Ajay Nirula, Peter Chen, JAMA	2021	931
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease Michael Charlton, Gregory T. Everson, Steven L. Flamm, Gastroenterology	2015	795
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection Roy T. Steigbigel, David A. Cooper, Princy Kumar, New England Journal of Medicine	2008	683
Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel Melanie Thompson, Michael J. Mugavero, K. Rivet Amico, Annals of Internal Medicine	2012	594
Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease Edward L. Murphy, Ann C. Collier, Leslie A. Kalish, Annals of Internal Medicine	2001	574
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection David A. Cooper, Roy T. Steigbigel, José M. Gatell, New England Journal of Medicine	2008	505
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials Joseph J. Eron, Benjamin Young, David A. Cooper, The Lancet Switchmrk 1Treatment And PreventionHuman RetrovirusClinical TrialsAntiviral Therapy	2010	312
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study Joseph J. Eron, Bonaventura Clotet, J. Durant, The Journal of Infectious Diseases	2012	306
Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States Jennifer E. Flythe, Magdalene M. Assimon, Matthew J. Tugman, American Journal of Kidney Diseases HemodialysisIntensive Care UnitsMedicineKidney FailureAcute Care	2020	231
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1 Brinda Emu, Jeffrey Fessel, Shannon Schrader, New England Journal of Medicine	2018	220

Page 1